WO2008045410A2 - Préparation sans alcool d'argatroban - Google Patents

Préparation sans alcool d'argatroban Download PDF

Info

Publication number
WO2008045410A2
WO2008045410A2 PCT/US2007/021533 US2007021533W WO2008045410A2 WO 2008045410 A2 WO2008045410 A2 WO 2008045410A2 US 2007021533 W US2007021533 W US 2007021533W WO 2008045410 A2 WO2008045410 A2 WO 2008045410A2
Authority
WO
WIPO (PCT)
Prior art keywords
salt
acid
argatroban
formulation
pharmaceutically acceptable
Prior art date
Application number
PCT/US2007/021533
Other languages
English (en)
Other versions
WO2008045410A3 (fr
Inventor
Nageswara R. Palepu
Original Assignee
Scidose Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/020725 external-priority patent/WO2008039473A2/fr
Application filed by Scidose Llc filed Critical Scidose Llc
Priority to US12/442,975 priority Critical patent/US20100076019A1/en
Publication of WO2008045410A2 publication Critical patent/WO2008045410A2/fr
Publication of WO2008045410A3 publication Critical patent/WO2008045410A3/fr
Priority to US13/618,532 priority patent/US20130023559A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention relates to argatroban and related compounds and to the solubilization thereof to yield injectable and other aqueous solutions of desired concentration in aqueous media without the need for alcohols or other solvents and/or without the use of saccharides.
  • Argininesulfonamides are known to have anti-thrombotic activities (see e.g., Japanese Patent No. 1382377). However, it is very difficult to obtain a solution containing any of the argininesulfonamides at high concentrations due to their general poor solubility in water. Therefore these compounds are generally not suitable for use in injection formulations containing them at high concentrations.
  • U.S. 5,214,052 attempts to solve this problem by dissolving these compounds in a dissolution media containing water, ethanol, and a saccharide (inclusive of monosaccharides, disaccharides, oligosaccharides and their reduced sugar alcohol counterparts).
  • Argatroban currently marketed by Encysive in the US is sold as a 2.5 ml vial of 100 mg/ml argatroban concentrate having 750 mg D-sorbitol, and 1000 mg dehydrated alcohol per ml, which concentrate is subsequently diluted to 1 mg/ml argatroban for actual use. While that formulation allows for advantages in packaging and dissolution to final concentration, it suffers from the drawback of having ethanol present in a not insignificant amount, especially when the patient in question is of smaller body weight.
  • An object of the invention is to provide a method for improving the solubility of argininesulfonamides in a completely aqueous system, in particular avoiding the use of organic solvents such as monoalcohols of 1-4 carbon atoms, especially ethanol, and still obtain solutions of sufficient concentration for use in parenteral administration.
  • a further object of the invention is to provide an argininesulfonamide formulation that is substantially free of saccharides, inclusive of mono-saccharides, di-saccharides, oligosaccharides, and their corresponding sugar alcohols.
  • Another object of the invention is to provide a dosage form of argininesulfonamide which is not as concentrated so that further dilution for use does not result in substantial waste of material in most typical administration settings.
  • a further object of the invention is to provide a dosage form of argininesulfonamide not requiring an extensively large dilution, yet be concentrated sufficiently to be convenient for preparing for use and less subject to dissolution errors than with current marketed argatroban.
  • Still a further object of the invention is to provide 1 mg/ml ready to administer solutions of argininesulfonamide in 5 ml to 500 ml vials and 25 ml to 500 ml infusion bags.
  • Yet another object of the invention is to provide an argininesulfonamide ready-to- administer formulation having a storage stability of at least about 18 months.
  • Still another object of the invention is to provide an argininesulfonamide ready-to- administer formulation having a substantial stability with respect to pH in a terminal sterilization operation.
  • An even further object of the invention is to provide an argininesulfonamide ready-to- administer formulation having a substantial stability with respect to degradation product in a terminal sterilization operation.
  • An even further object of the invention is to provide an argininesulfonamide ready-to- administer formulation having a substantial stability with respect to degradation product in the presence of an antioxidizing agent such as methionine in an aseptic operation or in a terminal sterilization operation.
  • Still another object of the invention is the use of lactobionic acid as a solubilizer and/or stabilizer to enhance the aqueous solubility as well as stability of argininesulfonamide.
  • Yet another object of the invention is to provide an argatroban ready to administer aqueous solution for injection having carbonate and/or bicarbonate ion present.
  • Still another object of the invention is to provide an argininesulfonamide aqueous formulation that can be incorporated into non-injectable dosage forms inclusive of ointments, creams, suppositories, liquid fill tablets, liquid fill capsules, and transdermal devices, among others.
  • Still another object of the invention is the use of lactobionic acid as a solubilizer and/or stabilizer to enhance the aqueous solubility as well as stability of argininesulfonamide.
  • the invention provides a method for dissolving argininesulfonamides comprising dissolving an argininesulfonamide (most preferably argatroban) in an aqueous, preferably, buffered system substantially free of lower alcohols and in the substantial absence of saccharides (mono-, di-, and oligo- saccharides and their corresponding sugar alcohols). Further, the invention provides pharmaceutical compositions containing the argininesulfonamides.
  • the invention provides a method for dissolving an argininesulfonamide comprising dissolving an N 2 -arylsulfonyl-L-arginine having general formula (I) or a pharmaceutically acceptable slat thereof
  • R 1 represents an unsubstituted or substituted 2-carboxypiperidino group (where there may be up to 5 substituents independently selected from alkyl, carboxy, an amidated carboxy (the amidated carboxy nitrogen being further unsubstituted or having one or two alkyl substituents that may be joined so as to form a 5, 6, or 7 membered ring with the amidated carboxy nitrogen), an esterified carboxy, or a pharmaceutically acceptable salt of the carboxy group), preferably a 4-alkyl-carboxypiperidino group, more preferably a (2R, 4R)-4-alkyl-2- carboxypiperidino group.
  • the alkyl group herein is a lower alkyl having 1 to 5 carbon atoms such as, without limitation, methyl, ethyl, propyl, isopropyl and butyl.
  • R 1 represents a (2R, 4R)-4-methyl-2-carboxypiperidino group.
  • R 2 represents a phenyl group or a condensed polycyclic compound residue.
  • the condensed polycyclic compound residue defined herein includes a benzene ring that binds to the sulfur atom of the sulfonyl group and is condensed with one or more other rings, which other rings may be carbocyclic or heterocyclic and which further has 3 to 14 carbon atoms as the ring- constituent atoms (exclusive of the ring atoms in the benzene ring that is attached to the sulfonyl sulfur atom).
  • the benzene ring included in the condensed polycyclic compound residue binds to the sulfur atom of the sulfonyl group in the general formula (I) at any position of the benzene ring, provided that the position on the benzene ring binding to the sulfur atom is not particularly limited.
  • the heteroatom or heteroatoms constituting the heterocyclic ring may be oxygen, nitrogen or sulfur atoms.
  • the other rings may be aromatic, or partially saturated, and in the case of a tricyclic group, the third ring not bound to the benzene ring may further be fully saturated.
  • the heteroring nitrogens may be further unsubstituted or further substituted with an alkyl, and the heteroring sulfur atoms may be unoxidized, mono-oxidized, or di-oxidized (i.e., -S-, -S(O)-, or -SO 2 -).
  • the condensed polycyclic compound residue is a dicyclic compound residue including benzene ring condensed with one other ring, preferably one five- or six- membered ring which may be heterocyclic or a tricyclic compound residue inclusive of the benzene ring condensed with two other rings, preferably two rings of five or six-members each which may be heterocyclic.
  • Examples of such condensed polycyclic compound residues include anthryl, phenanthryl, benzofuranyl, dibenzothienyl, phenoxthinyl, quinolyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, benzimidazolyl, fluorenyl, 2,3-dihydrobenzofuranyl, thioxathenyl, naphthyl, tetrahydronaphthyl, isoquinolyl, tetrahydroquinolyl and tetrahydroisoquinolyl.
  • R 2 can be substituted with one or more substituents selected from lower alkyl groups, lower alkoxy groups and lower alkyl-substituted amino groups.
  • the lower alkyl group is alkyl group having 1 to 5 carbon atoms, such as, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.
  • the lower alkoxy group is alkoxy group having 1 to 5 carbon atoms, such as, without limitation, methoxy, ethoxy, propoxy, isopropoxy and butoxy.
  • the lower alkyl-substituted amino group may be unsubstituted or further mono or di-substituted, each of such substituents being selected from lower alkyl having 1 to 5 carbon atoms, such as, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.
  • R 2 represents a 3-methyl-l,2,3,4-tetrahydro-8-quinolyl group.
  • any compound within the scope of formula I above that has one or more chiral centers is deemed to include the individual optical isomers as well as mixtures of those isomers, and any compound within the scope of formula I that is indicated as having chiral centers, whether or not referred to as an optical isomer, includes each of the individual optical isomers as well as mixtures thereof in any proportions, and any compound within the scope of formula I that is identified as an optical isomer includes reference to the other optical isomers and mixtures thereof in various proportions.
  • argininesulfonamides suitable for use in the invention include the following compounds and the pharmaceutically acceptable salts of each:
  • the argininesulfonamide used in the present invention is argatroban or a pharmaceutically acceptable salt thereof.
  • the invention can use the salts of argininesulfonamides having the general formula (I).
  • the salts may be acid addition salts (there being a sulfonamide group and in many of the compounds an additional carboxy group present) prepared by reacting the argininesulfonamide of general formula (I) with any pharmaceutically acceptable inorganic or organic acid such as, without limitation, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, citric acid, maleic acid, succinic acid, lactic acid, tartaric acid, gluconic acid, glucuronic acid, ethers of glucuronic aicd or gluconic acid (such as lactobionic acid), benzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid and p- toluenesulfonic acid.
  • any pharmaceutically acceptable inorganic or organic acid
  • the salts may be inorganic or organic salts prepared by reacting the argininesulfonamide of general formula (I) with any pharmceutically acceptable organic or inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, triethylamine, procaine, dibenzylamine, N, N'-dibenzylethylenediamine and N-ethylpiperidine.
  • organic or inorganic bases such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, triethylamine, procaine, dibenzylamine, N, N'-dibenzylethylenediamine and N-ethylpiperidine.
  • the argininesulfonamide and/or its salt is dissolved in an amino acid aqueous solution.
  • the amino acid used in the invention is preferably selected from arginine, glycine, methionine, or other amino acids with at least one basic group pKa >9.0 or mixtures thereof.
  • the amino acid can be used as the acid or a salt thereof or mixtures thereof. While either D- or L- or D 5 L- amino acids can be used, L-amino acids are generally preferred in this first embodiment. In another embodiment, discussed below, D,L-amino acids are generally preferred.
  • the pH of the drug and amino acid solution is adjusted to about 8.0 to about 10.0 with one or more pharmaceutically acceptable carboxylic acids such as, without limitation, acetic acid or any other carboxylic acid or dicarboxylic acid or hydroxy carboxylic acid; and may be adjusted with either the acid itself, or a salt thereof, or mixtures thereof if an appropriate pH can be reached using such salt or mixture of salt and acid.
  • carboxylic acids such as, without limitation, acetic acid or any other carboxylic acid or dicarboxylic acid or hydroxy carboxylic acid; and may be adjusted with either the acid itself, or a salt thereof, or mixtures thereof if an appropriate pH can be reached using such salt or mixture of salt and acid.
  • Preferred amino acids are arginine, glycine, and methionine. In this first embodiment arginine and glycine are more highly preferred, while in a second embodiment, discussed more specifically below, methionine is a more preferred amino acid.
  • the amino acid when having buffering capacity in the desired region, can be self-buffering so that a separate buffer is not required; in this case pH adjustment can be accomplished with inorganic acids and bases (e.g., HCl or NaOH, among others).
  • inorganic acids and bases e.g., HCl or NaOH, among others.
  • the amino acid may be a dicarboxylic amino acid selected from formulas II and III
  • a and B are each independently selected from (a) a branched or unbranched alkyl of 0-6 carbons, provided that the sum of the carbon atoms in A and B do not exceed 6; (b) a branched or unbranched heteroalkyl having up to 2 heteroatoms selected from N and O, provided that the sum of the carbon and heteroatoms in A and B do not exceed 6; (c) 5-6 membered cycloalkyl, 5- 6 membered heteroalkyl having up to 2 heteroatoms selected form N, O, and S; (d) 6 membered aryl or heteroaryl having up to 2 hetero atoms selected from N, O, and S; preferably dicarboxylic amino acids of formula II are those where A and B are both limited to alkyls of 0-6 carbons, more preferably those where the amino group is in an alpha or beta position to at least one of the carboxylic groups, and even more preferably where the two carboxylic acid groups are separated by at least 2 carbon atoms.
  • ring C is a six-membered aromatic or heteroaromatic ring or partially or fully saturated analog thereof, having up to 2 heteroatoms selected from N, O, and S and on which the amino and the carboxylic acid groups can be present at any available position of such ring C, and each n is independently an interger of 0-3, preferably each n is zero.
  • Exemplary dicarboxylic amino acid of formula II are, without limitation, glutamic acid and aspartic acid.
  • An exemplary amino acid with formula III is amino phthalic acid.
  • the pKa of the basic function (or of at least one basic function if more than one is present) should be greater than about 9.
  • the amino acid is generally present in amounts that are about 1.5 to about 2.5, preferably about 2 times the amount of the compound of formula (I) present (based on the non- salt form of the compound of formula (I)).
  • the carboxylic acid other than carbonic acid salt
  • the carbonic acid salt is generally present in an amount of about 3.0 to about 9.8 (based on CO 3 ) times the amount of the compound of formula (I) present (based on the non-salt form of the compound of formula (I)), preferably about 1.4 to about 5.2 times, more preferably about 1.5 to about 2.5 times, more preferably about 1.9 to about 2.0 times when the amino acid is absent and preferably about 3.0 to about 5.2 times, more preferably about 4.1 to about 4.2 times when the amino acid is present.
  • those of ordinary skill in the art will be
  • Water as used in the present invention includes aqueous injectable fluids including, but not limited to distilled water, purified water, water for injection, a physiological saline, Ringer's Solution, Lactated Ringer's Solution and 5% dextrose solution, and any of these may be used for diluting concentrates.
  • aqueous injectable fluids including, but not limited to distilled water, purified water, water for injection, a physiological saline, Ringer's Solution, Lactated Ringer's Solution and 5% dextrose solution, and any of these may be used for diluting concentrates.
  • distilled water, purified water or water for injection is used with a post formulation sterilization procedure, or preferably water for injection is used if post-formulation sterilization is not being used.
  • the manner of how to dissolve the argininesulfonamide having the general formula (I) in water and optionally in an amino acid aqueous solution is not particularly limited.
  • the amino acid (or its salt or a mixture of the amino acid and its salt) when present, is dissolved in water and then the pH is adjusted upward, if need be, to about pH 8.7 to about 10 with the addition of inorganic or organic base (or salts of carboxylic acid or mixtures of its salts and their conjugate acids or conjugate bases (inclusive of alkali metal salt(s) and ammonium salts of carbonic acid)) thereto followed by mixing.
  • inorganic or organic base or salts of carboxylic acid or mixtures of its salts and their conjugate acids or conjugate bases (inclusive of alkali metal salt(s) and ammonium salts of carbonic acid)
  • the argininesulfonamide is slowly added while stirring until complete dissolution. If desired, but not required, the pH can then be adjusted downward. Where concentrates are to be made for subsequent dilution, higher pH can be tolerated for the dissolution and storage phases as the subsequent dilution will bring the pH closer to physiologic pH before injection. Concentrates having the amino acid in the range of 50 mg/ml (especially when using arginine as the amino acid) will have a pH as high as about 11 to about 11.5 before addition of the argininesulfonamide. In these concentrates, the argininesulfonamide is dissolved and the pH is adjusted downward into the range of about 8.7 to 9.5 as discussed above using an appropriate acid or buffer.
  • the ready-to- administer product pH should generally not be greater than about pH about 9.5, preferably not greater than about 9.2, and more preferably is usually about pH 8.7, about 8.8, about 8.9, about 9.0, about 9.1, or about 9.2. Certain advantageous ready to use formulations of the present invention have a pH of about 8.7, while certain other advantageous ready-to-use formulations of the present invention have a pH of about 9.2.
  • the temperature on dissolution is not particularly limited.
  • the argininesulfonamide is dissolved in water, however, it is preferable to warm the water to about 40 0 C to about 80 0 C for accelerating the dissolution rate, about 70 0 C being advantageous in a number of situations.
  • the concentration of argininesulfonamide in the solution can be selected within a wide range depending on the intended uses. According to the invention, the solution in which the argininesulfonamide is dissolved may result in concentrations of the argininesulfonamide that are several folds higher than the concentrations of the argininesulfonamide typically obtained with the solubility of the argininesulfonamide in water alone.
  • the argatroban when argatroban or a pharmaceutically acceptable salt thereof is the active agent, the argatroban can be dissolved up to (based on an equivalent of non-salt form argatroban) about 7.5 mg/ml, preferably about 6 mg/ml, most preferably about 5 mg/ml.
  • An additional embodiment within the invention is a ready-to- administer solution of about 0.8 to about 1.25 mg/ml, preferably about 0.9 to about 1.1 mg/ml, more preferably about 1 mg/ml compound of formula (I). All amounts presented are amounts of compound of formula (I) free compound, that is the non-salt. Corresponding amounts of various salts will be readily known to those of ordinary skill in the art by routine calculation.
  • the argininesulfonamide compound of formula (I), preferably argatroban, or a pharmaceutically acceptable salt thereof is dissolved in an aqueous solution of a gluconic or glucuronic acid (or a sugar ether of either, where the sugar position 1 is etherified with one of the hydroxyl groups of the gluconic or glucuronic acid, preferably the ether is lactobionic acid or a salt thereof) and/or with an alkali metal (e.g., sodium or potassium) or ammonium salt, preferably a sodium salt, of carbonic acid (e.g., sodium carbonate, sodium bicarbonate, and mixtures thereof) and optionally an amino acid or salt thereof.
  • a gluconic or glucuronic acid or a sugar ether of either, where the sugar position 1 is etherified with one of the hydroxyl groups of the gluconic or glucuronic acid, preferably the ether is lactobionic acid or a salt thereof
  • an alkali metal e
  • the salts are pharmaceutically acceptable salts, and in the case of use of the solution as an injectable, the salt is compatible with its use in an injectable formulation.
  • the formulation comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof; a gluconic acid or glucuronic acid, or an ether of either or a pharmaceutically acceptable salt thereof (preferably lactobionic acid or a pharmaceutically acceptable salt thereof) and/or an alkali metal or ammonium salt of carbonic acid, preferably a sodium salt of carbonic acid or mixture of sodium salts of carbonic acid; optionally an amino acid, preferably an anti-oxidant amino acid (more preferably methionine), arginine, or glycine, either in the D-, L-, or D,L- form, preferably as the D,L- form, the amino acid optionally in the form of a pharmaceutically acceptable salt thereof; and water (which water may further contain an optional inert osmolarity adjuster (other than
  • substantially free when referring to a lower alcohol means less than about 5% v/v, preferably less than about 2.5%, more preferably less than about 1%, more preferably less than about 0.5% v/v; while when referring to "saccharide” means less than about 10% w/v, preferably less than about 7.5%, more preferably less than about 5%, still more preferably less than about 2.5%, even more preferably less than about 1%, yet more preferably less than about 0.05% w/v.
  • Formulations having the required components and either or both lower alcohols and saccharides are within the present invention, should one so desire, but the emphasis of the invention is primarily on the avoidance of the lower alcohol or saccharide and particularly the avoidance of both.
  • Inclusion of methionine or another anti-oxidant amino acid improves the product stability especially with respect to terminal sterilization, and is therefore one particularly preferred embodiment.
  • the water it is preferable to first heat the water, preferably to boiling, then allow the water to cool to a temperature of about 30-50 0 C, preferably about 35 0 C.
  • the carboxylic acid preferably lactobionic acid or pharmaceutically acceptable salt thereof and/or alkali metal salt or ammonium salt of carbonic acid
  • any optional amino acid is added and dissolved.
  • the compound of formula (I) (or a pharmaceutically acceptable salt thereof) is added and dissolved.
  • the amino acid and carboxylic acid addition steps can be reversed, if desired or the amino acid can be added after the compound of formula (I).
  • the pH is adjusted as convenient at any point prior to the addition of the compound of formula (I) or pharmaceutically acceptable salt thereof to a pH in excess of about 8.5, preferably in excess of about 8.6, more preferably to about pH 8.7 to about 9.5, more particularly about pH 8.7 to about 9.2, still more preferably about 8.7, about 8.8, about 8.9, about 9.0, about 9.1 or about 9.2, so as to aid in the dissolution of the compound of formula (I).
  • a concentrate formulation may be prepared within the instant invention which has a substantially high pH, while the ready-to-use formulations will have a generally weakly alkaline pH, generally greater than about 8.6 and generally less than about 9.2.
  • the solution thus obtained containing any of the argininesulfonamides having the general formula (I), the amino acid, water and carboxylic acid constitutes a first embodiment of the pharmaceutical composition of the invention, while the solution containing (a) the compound of formula(I); (b) water; (c) (1) gluconic acid, glucuronic acid, and/or ether thereof, and/or (c) (2) an alkali metal or ammonium salt or mixtures of alkali metal or ammonium salts of carbonic acid; and (d) optional (preferably anti-oxidant) amino acid constitutes a second embodiment, and the solution containing the argatroban, amino acid, and water with or without the carboxylic acids constitutes a third embodiment of the invention.
  • carboxylic acid in the first embodiment is selected from gluconic acid, glucuronic acid, the ether of either (especially lactobionic acid) and alkali metal or ammonium salt or mixture of alkali metal or ammonium salts of carbonic acid; and the amino acid in the first embodiment is an anti-oxidant amino acid.
  • compositions of the invention are useful for treating thrombosis and for treating and/or prophylaxis of any other condition for which the active agents are already known to be useful. Accordingly, the pharmaceutical compositions can be used as antithrombotic agents.
  • the pharmaceutical composition of the invention may contain antiseptic, anti-oxidant, soothing agents and the like. And, if necessary any pharmaceutical ingredient(s) other than the argininesulfonamides may be added to form a combined preparation, provided such other ingredient is not unacceptable for the indication and route of administration; however, the invention compositions and processes are generally substantially free of, if not totally free of (1) ethyl alcohol, more preferably any lower alcohol of 1 -4 carbon atoms or (2) a saccharide, preferably a monosaccharide or disaccharide or oligosaccharide, more preferably any saccharide (wherein saccharide herein optionally includes the reduced sugar alcohol counterparts thereto), or (3) both (1) and (2).
  • compositions within the invention may contain either or both of the alcohols or saccharides (in more than insignificant amounts, they are preferably substantially free, more preferably totally free of one or both of these materials as stated earlier.
  • the primary composition of the invention in the first embodiment is a pharmaceutical injectable and is administered as an injection.
  • This injectable composition may further contain stabilizer, buffer, preservative and the like, which are acceptable for injection.
  • the injectable composition according to the invention is prepared to contain an argininesulfonamide at a high concentration, which is used by diluting with water, electrolyte (e.g., normal saline, among others), carbohydrate solution (e.g., 5% Dextrose), Ringer's solution or the like at or close to the time of administration (such as by infusion and/or dialysis).
  • the concentrated formulation may contain amounts of up to about 7.5 mg (based on free argininesulfonamide (non-salt form), preferably up to about 5 mg per ml.
  • argininesulfonamide this is generally diluted for administration to about 1 mg (based on argininesulfonamide non-salt form) per ml. Dilution of the concentrate to other concentrations for use as an injection will be within the ordinary skill in the art.
  • the formulation can also be prepared as a lyophilizate or as a sterile dry fill product that can be reconstituted with appropriate diluent diluent to either the concentrate concentrations of this embodiment or to the ready-to-use concentrations in the second embodiment..
  • the primary composition of the invention second embodiment is also as a pharmaceutically acceptable injection formulation, primarily as a ready-to-administer composition.
  • the argininesulfonamide (or salt thereof based on free argininesulfonamide), preferably argatroban, is present in a concentration of no more than about 1.25 mg/ml, preferably about 1.1 mg/ml, more preferably about 1 mg/ml, in a pH of about 8.5 to about 9.2, preferably about 8.6 to about 8.9, more preferably about pH 8.7 to about 8.9 in a water solution containing (a) as a carboxylic acid, at least one member selected from (1) gluconic acid, glucuronic acid, and sugar ethers thereof, especially lactobionic acid and pharmaceutically acceptable salts thereof and/or (2) alkali metal salt or ammonium salt or mixture of alkali metal salts and/or ammonium salts of carbonic acid, and optionally (b) at least one (preferably antioxidant) amino acid or pharmaceutical
  • the concentrate can be diluted with sufficient water of a suitable pH, with or without the amino acid or the carboxylic acid.
  • the osmotic adjuster is any injectably suitable osmotic adjuster but preferably is not a saccharide or sugar alcohol, especially when an alcohol of 1 -4 carbon atoms is present in the formulation.
  • the pharmaceutical composition of the invention is a solution for topical application, an ointment or a cream (in which the solution is taken up by an appropriate topical ointment or cream base), or a suppository (in which the solution is taken up by an appropriate suppository base).
  • the pharmaceutical composition is used as the solution for topical application, the solution prepared above can be used as it is, or upon dilution (the concentration for use is not limited to 1.0 mg/ml).
  • the solution typically concentrated
  • the transdermal dosage form When used for transdermal administration, is one generally capable of containing a solution such as (without limitation) a reservoir type transdermal having (without limitation) an active agent reservoir defined by a space between an impermeable backing, and a permeable skin contacting layer which itself is covered by a removable impermeable layer (prior to use).
  • the transdermal dosage form may contain the dissolved argatroban in a monolithic layer which may or may not further contain adhesive in such monolithic layer and which monolithic layer is covered by a removable impermeable layer (prior to use).
  • the impermeable removable layer is removed and the remainder of the device is applied to the patient's skin allowing drug to flow into the patient's skin.
  • Argatroban is dissolved (to a concentration of 5 mg/ml) in an aqueous system containing 50 mg/ml arginine with pH adjusted to 9.0 with acetic acid. The dissolution of argatroban is carried out at 50 C.
  • Example 3 Argatroban is dissolved (to a concentration of 5 mg/ml) in an aqueous system containing 50 mg/ml arginine with pH adjusted to 9.0 with tartaric acid. The dissolution of argatroban is carried out at 25 0 C.
  • Argatroban is dissolved (to a concentration of 5 mg/ml) in an aqueous system containing 50 mg/ml arginine with pH adjusted to 9.0 with citric acid. The dissolution of argatroban is carried out at 25 0 C.
  • Argatroban is dissolved (to a concentration of 5 mg/ml) in an aqueous system containing 50 mg/ml arginine with pH adjusted to 9.0 with adipic acid. The dissolution of argatroban is carried out at 25 C.
  • Argatroban is dissolved (to a concentration of 5 mg/ml) in an aqueous system containing 50 mg/ml lysine with pH adjusted to 9.0 with acetic acid. The dissolution of argatroban is carried out at 25 0 C. [0071] Example 7
  • Argatroban is dissolved (to a concentration of 5 mg/ml) in an aqueous system containing 50 mg/ml arginine with pH adjusted to 10.0 with acetic acid. The dissolution of argatroban is carried out at 25 0 C.
  • Argatroban is dissolved (to a concentration of 5 mg/ml) in an aqueous system containing 50 mg/ml arginine with pH adjusted to 8.0 with acetic acid. The dissolution of argatroban is carried out at 25 0 C.
  • Rl and R2 are selected as set forth in the table below is used and the mg amounts indicated in each prior Example is of the free compounds of this example rather than of argatroban:
  • Example 1 The solution of Example 1 is taken up into a pharmaceutically acceptable cream or ointment base (such as Aquaphor) and used as a topical application form.
  • a pharmaceutically acceptable cream or ointment base such as Aquaphor
  • Example 13 [0085] The solution of Example 1 is applied onto an impermeable backing layer and covered with a laminate made of a permeable membrane and a distally located impermeable release liner and the assemble is fused together to create a transdermally administrable dosage form of the solution of Example 1.
  • Example 1 The solution of Example 1 is taken up into a polyethylene glycol 8000 base to prepare a suppository formulation of argatroban.
  • Example 14 is repeated except that the solution pH is adjusted to about 8.7 after addition of the lactobionic acid, but before the addition of the argatroban.
  • Example 16 [0092] Example 14 is repeated except that the amounts of lactobionic acid and argatroban are increased by an additional 10% and after the argatroban has been dissolved, optionally additional water at pH about 8.7 is added to bring the final concentration of argatroban to about 1 mg/ml and the final concentration of lactobionic acid to about 2 mg/ml.
  • Examples 15-16 are repeated except that in Examples 18-19, DL-methionine is added before the lactobionic acid.
  • Examples 16-16 are repeated except that in Examples 20-22, DL-methionine is added after the lactobionic acid, but before the argatroban; and in Examples 23-25, D,L-methionine is added after the argatroban, in each of Examples 23-25 in an amount to result in a concentration of about 2 mg/ml D,L-methionine, and in Examples 20-22 in an amount of about 10% greater than in Examples 17-19.
  • Glycine was dissolved in water in an amount sufficient to achieve a glycine moiety final concentration of 2 mg/ml. The pH was then adjusted with IN sodium hydroxide to about 9.2. Sufficient argatroban was added thereto to result in a final argatroban moiety concentration of about 1 mg/ml. The final pH was adjusted, if needed, to about 9.2 with IN sodium hydroxide.
  • Example 29 is repeated except that lactobionic acid is added in an amount to result in a final lactobionic acid concentration of about 2 mg/ml after the glycine is dissolved but before the pH is adjusted, and the pH is adjusted to 8.5 (Example 30), 8.7 (Example 31), 9.0 (Example 32), 9.5 (Example 33), or 10.0 (Example 34).
  • Example 35 A, C, D, and E is repeated is repeated is repeated except that the glycine is replaced by aspartic acid 2mg/ml in Example 37, by glutamic acid in Example 38, and by aminophthalic acid in Example 39.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Préparation aqueuse d'argatroban et de composés connexes ainsi qu'une préparation reconstituable, chacune étant sensiblement, voire totalement, sans alcool. De plus, ces préparations sont sensiblement, voire totalement, sans mono-, di-, et oligosaccharides. Un mode de réalisation préféré concerne une dose injectable prête à l'emploi de 1mg/ml contenant de l'argatropan, de l'acide lactobionique et de la méthionine.
PCT/US2007/021533 2006-09-27 2007-10-09 Préparation sans alcool d'argatroban WO2008045410A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/442,975 US20100076019A1 (en) 2006-10-11 2007-10-09 Alcohol free formulation of argatroban
US13/618,532 US20130023559A1 (en) 2006-09-27 2012-09-14 Alcohol free formulation of argatroban

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85072506P 2006-10-11 2006-10-11
US60/850,725 2006-10-11
PCT/US2007/020725 WO2008039473A2 (fr) 2006-09-27 2007-09-26 Préparation sans alcool d'argatropan
US11/904,067 US7589106B2 (en) 2006-09-27 2007-09-26 Alcohol free formulation of argatroban
USPCT/US07/20725 2007-09-26
US11/904,067 2007-09-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/020725 Continuation-In-Part WO2008039473A2 (fr) 2006-09-27 2007-09-26 Préparation sans alcool d'argatropan

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/618,532 Continuation US20130023559A1 (en) 2006-09-27 2012-09-14 Alcohol free formulation of argatroban

Publications (2)

Publication Number Publication Date
WO2008045410A2 true WO2008045410A2 (fr) 2008-04-17
WO2008045410A3 WO2008045410A3 (fr) 2008-06-12

Family

ID=39283418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021533 WO2008045410A2 (fr) 2006-09-27 2007-10-09 Préparation sans alcool d'argatroban

Country Status (1)

Country Link
WO (1) WO2008045410A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2598148A2 (fr) * 2010-07-28 2013-06-05 Eagle Pharmaceuticals, Inc. Compositions pharmaceutiques contenant du pemetrexed présentant une stabilité en stockage prolongé
US11793813B2 (en) 2016-02-19 2023-10-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232315B1 (en) * 1998-09-28 2001-05-15 Merck & Co., Inc. Method for treating inflammatory diseases by administering a thrombin inhibitor
WO2004026252A2 (fr) * 2002-09-23 2004-04-01 The Regents Of The University Of Michigan Traitements du gliome
US20040242585A1 (en) * 2003-05-20 2004-12-02 Rawson Thomas E. Acylsulfamide inhibitors of factor VIIa

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232315B1 (en) * 1998-09-28 2001-05-15 Merck & Co., Inc. Method for treating inflammatory diseases by administering a thrombin inhibitor
WO2004026252A2 (fr) * 2002-09-23 2004-04-01 The Regents Of The University Of Michigan Traitements du gliome
US20040242585A1 (en) * 2003-05-20 2004-12-02 Rawson Thomas E. Acylsulfamide inhibitors of factor VIIa

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2598148A2 (fr) * 2010-07-28 2013-06-05 Eagle Pharmaceuticals, Inc. Compositions pharmaceutiques contenant du pemetrexed présentant une stabilité en stockage prolongé
WO2012015810A3 (fr) * 2010-07-28 2013-08-08 Eagle Pharmaceuticals, Inc. Compositions pharmaceutiques contenant du pemetrexed présentant une stabilité en stockage prolongé
EP2598148A4 (fr) * 2010-07-28 2014-05-28 Eagle Pharmaceuticals Inc Compositions pharmaceutiques contenant du pemetrexed présentant une stabilité en stockage prolongé
US11793813B2 (en) 2016-02-19 2023-10-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations

Also Published As

Publication number Publication date
WO2008045410A3 (fr) 2008-06-12

Similar Documents

Publication Publication Date Title
AU2015256331B2 (en) Formulations of Cyclophosphamide liquid concentrate
WO2016059588A1 (fr) Composition injectable stable de bivalirudine et son procede de preparation
US20170202901A1 (en) Stable compositions of peptide epoxy ketones
CN111093625A (zh) 达托霉素制剂
JP2016521731A (ja) 抗がん剤を含む安定な水溶性医薬組成物
WO2010119741A1 (fr) Préparation à usage externe
WO2017002030A1 (fr) Formulations liquides stables de melphalan
WO2013024495A1 (fr) Formulations pharmaceutiques de cabazitaxel
CA2669727C (fr) Preparation sans alcool d'argatropan
EA033988B1 (ru) Инъецируемые фармацевтические композиции лефамулина
JP6347784B2 (ja) 神経筋遮断薬の安定化水性組成物
US7094414B2 (en) Famotidine injections
US20190358249A1 (en) Injectable Combination Products Of Fosaprepitant And 5-HT3 Blocker
US20120208887A1 (en) Stable, liquid, ready-to-use ketoprofen formulations
WO2008045410A2 (fr) Préparation sans alcool d'argatroban
US20100076019A1 (en) Alcohol free formulation of argatroban
TW200808690A (en) Aqueous pharmaceutical formulation of 4-[((4-carboxybutyl)-{2-[(4-phenethylbenzyl)oxy]-phenethyl}amino)methyl]benzoic acid
JP2010504971A5 (fr)
US7687516B2 (en) Alcohol free formulation of argatroban
JPH0576929B2 (fr)
CN101516370A (zh) 阿加曲班的无醇制剂
TWI327910B (fr)
AU2008250717A1 (en) Aqueous pharmaceutical preparation
US20190070136A1 (en) Parenteral compositions of carmustine
WO2019130228A1 (fr) Compositions liquides stables de melphalan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07852597

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12442975

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07852597

Country of ref document: EP

Kind code of ref document: A2